Estrogen receptors as potential therapeutic target in endometrial cancer

References

• Meyer MR, Clegg DJ, Prossnitz ER, et al. Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. Acta Physiol. 2011;203(1):259–269.
   PubMedGoogle Scholar
• Barton M. Cholesterol and atherosclerosis: modulation by oestrogen. Curr Opin Lipidol. 2013;24(3):214–220.
   PubMed Web of Science ®Google Scholar
• Arevalo MA, Azcoitia I, Garcia-Segura LM. The neuroprotective actions of oestradiol and oestrogen receptors. Nat Rev Neurosci. 2015;16(1):17–29.
   PubMed Web of Science ®Google Scholar
• Roberts H, Hickey M. Managing the menopause: an update. Maturitas. 2016;86:53–58.
   PubMed Web of Science ®Google Scholar
• Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res. 2003;9(6):1980–1989.
   PubMed Web of Science ®Google Scholar
• Benagiano G, Bastianelli C, Farris M. Contraception today. Ann N Y Acad Sci. 2006;1092(1):1–32.
   PubMedGoogle Scholar
• Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006;116(3):561–570.
   PubMed Web of Science ®Google Scholar
• Jia M, Dahlman-Wright K, Gustafsson JÅ. Estrogen receptor alpha and beta in health and disease. Best Pract Res Clin Endocrinol Metab. 2015;29(4):557–568.
   PubMed Web of Science ®Google Scholar
• Filardo EJ, Quinn JA, Bland KI, et al. Estrogen-induced activation of erk-1 and erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol. 2000;14(10):1649–1660.
   PubMed Web of Science ®Google Scholar
• Leslie KK, Thiel KW, Goodheart MJ, et al. Endometrial cancer. Obstet Gynecol Clin North Am. 2012;39(2):255–268.
   PubMedGoogle Scholar
• Prossnitz ER, Barton M. Estrogen biology: new insights into GPER function and clinical opportunities. Mol Cell Endocrinol. 2014;389(1-2):71–83.
   PubMed Web of Science ®Google Scholar
• Vivacqua A, Bonofiglio D, Recchia AG, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol. 2006;20(3):631–646.
   PubMedGoogle Scholar
• Rodriguez AC, Blanchard Z, Maurer KA, et al. Estrogen signaling in endometrial cancer: a key oncogenic pathway with several open questions. Horm Cancer. 2019;10(2-3):51–63.
   PubMedGoogle Scholar
• Xu S, Yu S, Dong D, et al. G protein-coupled estrogen receptor: a potential therapeutic target in cancer. Front Endocrinol. 2019;10:725.
   PubMedGoogle Scholar
• Droog M, Nevedomskaya E, Dackus GM, et al. Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors. Proc Natl Acad Sci U S A. 2017;114(8):E1316–E1325.
   PubMedGoogle Scholar
• Groothuis PG, Dassen HH, Romano A, et al. Estrogen and the endometrium: lessons learned from gene expression profiling in rodents and human. Hum Reprod Update. 2007;13(4):405–417.
   PubMedGoogle Scholar
• Reed BG, Carr BR. The normal menstrual cycle and the control of ovulation. South Dartmouth, MA: MDText.com, Inc; 2015.
   Google Scholar
• Mesen TB, Young SL. Progesterone and the luteal phase: a requisite to reproduction. Obstet Gynecol Clin North Am. 2015;42(1):135–151.
   PubMedGoogle Scholar
• National Cancer Institute. SEER Cancer Stat Facts: Uterine cancer. Bethesda, Maryland: National Cancer Institute. Available from: https://seer.cancer.gov/statfacts/html/corp.html. Accessed Oct 2018.
   Google Scholar
• Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health. 2014;6:429.
   PubMedGoogle Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Shen F, Gao Y, Ding J, et al. Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer? Oncotarget. 2017;8(1):506–511.
   PubMedGoogle Scholar
• Petrie WK, Dennis MK, Hu C, et al. G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth. Obst Gynecol Int. 2013;2013:1–17.
   Google Scholar
• Ma X, Ma CX, Wang J. Endometrial carcinogenesis and molecular signaling pathways. AJMB. 2014;04(03):134–149.
   Google Scholar
• Setiawan VW, Yang HP, Pike MC, Australian National Endometrial Cancer Study Group, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607–2618.
   PubMed Web of Science ®Google Scholar
• Kandoth C, Schultz N, Cherniack AD, et al. Cancer genome atlas research N. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.
   PubMed Web of Science ®Google Scholar
• Hewitt SC, Korach KS. Estrogen receptors: structure, mechanisms and function. Rev Endocr Metab Disord. 2002;3(3):193–200.
   PubMedGoogle Scholar
• Pietras RJ, Szego CM. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 1977;265(5589):69–72.
   PubMed Web of Science ®Google Scholar
• Kumar V, Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 1988;55(1):145–156.
   PubMed Web of Science ®Google Scholar
• Joseph R, Orlov YL, Huss M, et al. Integrative model of genomic factors for determining binding site selection by estrogen receptor-α. Mol Syst Biol. 2010;6:456.
   PubMedGoogle Scholar
• Krishnan V, Wang X, Safe S. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem. 1994;269(22):15912–15917.
   PubMedGoogle Scholar
• Safe S, Kim K. Nonclassical genomic ER/Sp and ER/AP-1 signaling pathways. J Mol Endocrinol. 2008;41(5):263–275.
   PubMed Web of Science ®Google Scholar
• Coons LA, Hewitt SC, Burkholder AB, et al. DNA sequence constraints define functionally active steroid nuclear receptor binding sites in chromatin. Endocrinology 2017;158(10):3212–3234.
   PubMedGoogle Scholar
• Hah N, Murakami S, Nagari A, et al. Enhancer transcripts mark active estrogen receptor binding sites. Genome Res. 2013;23(8):1210–1223.
   PubMed Web of Science ®Google Scholar
• Carleton JB, Berrett KC, Gertz J. Multiplex enhancer interference reveals collaborative control of gene regulation by estrogen receptor α-bound enhancers. Cell Syst. 2017;5(4):333–344.e5.
   PubMedGoogle Scholar
• Carleton JB, Berrett KC, Gertz J. Dissection of enhancer function using multiplex CRISPR-based enhancer interference in cell lines. J Vis Exp. 2018;(136):e57883.
   Google Scholar
• Droog M, Nevedomskaya E, Kim Y, et al. Comparative cistromics reveals genomic cross-talk between FOXA1 and ERα in tamoxifen-associated endometrial carcinomas. Cancer Res. 2016;76(13):3773–3784.
   PubMedGoogle Scholar
• Métivier R, Penot G, Flouriot G, et al. Synergism between ERα transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 α-helical core and for a direct interaction between the N-and C-terminal domains. Mol Endocrinol. 2001;15(11):1953–1970.
   PubMedGoogle Scholar
• Raglan O, Kalliala I, Markozannes G, et al. Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer. 2019;145(7):1719–1730.
   PubMed Web of Science ®Google Scholar
• Cleland WH, Mendelson CR, Simpson ER. Aromatase activity of membrane fractions of human adipose tissue stromal cells and adipocytes. Endocrinology. 1983;113(6):2155–2160.
   PubMedGoogle Scholar
• Giviziez CR, Sanchez EG, Approbato MS, et al. Obesity and anovulatory infertility: a review. JBRA Assist Reprod. 2016;20(4):240–245.
   PubMedGoogle Scholar
• Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome: a review analysis. Hippokratia. 2009;13(2):90.
   PubMed Web of Science ®Google Scholar
• Dinkelspiel HE, Wright JD, Lewin SN, et al. Contemporary clinical management of endometrial cancer. Obstet Gynecol Intl. 2013;2013:1–11.
   Google Scholar
• Baker J, Obermair A, Gebski V, et al. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol. 2012;125(1):263–270.
   PubMed Web of Science ®Google Scholar
• MacKay HJ, Freixinos VR, Fleming GF. Therapeutic targets and opportunities in endometrial cancer: update on endocrine therapy and nonimmunotherapy targeted options. Am Soc Clin Oncol Educ Book. 2020;40(40):245–255.
   Google Scholar
• Carmeci C, Thompson DA, Ring HZ, et al. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 1997;45(3):607–617.
   PubMed Web of Science ®Google Scholar
• Thomas P, Pang Y, Filardo EJ, et al. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005;146(2):624–632.
   PubMed Web of Science ®Google Scholar
• Revankar CM, Cimino DF, Sklar LA, et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005;307(5715):1625–1630.
   PubMed Web of Science ®Google Scholar
• Filardo EJ. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol. 2002;80(2):231–238.
   PubMedGoogle Scholar
• Zhang L, Li Y, Lan L, et al. Tamoxifen has a proliferative effect in endometrial carcinoma mediated via the GPER/EGFR/ERK/cyclin D1 pathway: a retrospective study and an in vitro study. Mol Cell Endocrinol. 2016;437:51–61.
   PubMed Web of Science ®Google Scholar
• He YY, Cai B, Yang YX, et al. Estrogenic G protein‐coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin‐6 secretion via the MEK/ERK mitogen‐activated protein kinase pathway. Cancer Sci. 2009;100(6):1051–1061.
   PubMed Web of Science ®Google Scholar
• Tsai CL, Wu HM, Lin CY, et al. Estradiol and tamoxifen induce cell migration through GPR30 and activation of focal adhesion kinase (FAK) in endometrial cancers with low or without nuclear estrogen receptor α (ERα). PLoS One. 2013;8(9):e72999.
   PubMedGoogle Scholar
• Albitar L, Pickett G, Morgan M, et al. Models representing type I and type II human endometrial cancers: ishikawa H and Hec50co cells. Gynecol Oncol. 2007;106(1):52–64.
   PubMedGoogle Scholar
• Wei Y, Zhang Z, Liao H, et al. Nuclear estrogen receptor-mediated notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation. Oncol Rep. 2012;27(2):504–510.
   PubMed Web of Science ®Google Scholar
• Du GQ, Zhou L, Chen XY, et al. The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells. Biochem Biophys Res Commun. 2012;420(2):343–349.
   PubMedGoogle Scholar
• Lin BC, Suzawa M, Blind RD, et al. Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Cancer Res. 2009;69(13):5415–5423.
   PubMedGoogle Scholar
• Prossnitz ER, Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol. 2009;308(1-2):32–38.
   PubMed Web of Science ®Google Scholar
• Prossnitz ER. GPER modulators: opportunity nox on the heels of a class akt. J Steroid Biochem Mol Biol. 2018;176:73–81.
   PubMedGoogle Scholar
• Albanito L, Sisci D, Aquila S, et al. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology. 2008;149(8):3799–3808.
   PubMedGoogle Scholar
• Jung J. Role of G protein-coupled estrogen receptor in cancer progression. Toxicol Res. 2019;35(3):209–214.
   PubMed Web of Science ®Google Scholar
• Deng J, Wang W, Yu G, et al. MicroRNA-195 inhibits epithelial-mesenchymal transition by targeting G protein-coupled estrogen receptor 1 in endometrial carcinoma. Mol Med Rep. 2019;20(5):4023–4032.
   PubMedGoogle Scholar
• De Marco P, Bartella V, Vivacqua A, et al. Insulin-like growth factor-I regulates GPER expression and function in cancer cells. Oncogene. 2013;32(6):678–688.
   PubMedGoogle Scholar
• Li Y, Jia Y, Bian Y, et al. Autocrine motility factor promotes endometrial cancer progression by targeting GPER-1. Cell Commun Signal. 2019;17(1):1–4.
   PubMed Web of Science ®Google Scholar
• Ososki AL, Kennelly EJ. Phytoestrogens: a review of the present state of research. Phytother Res. 2003; Sep17(8):845–869.
   PubMedGoogle Scholar
• Singleton DW, Khan SA. Xenoestrogen exposure and mechanisms of endocrine disruption. Front Biosci. 2003;8:S110–S8.
   PubMed Web of Science ®Google Scholar
• Maggiolini M, Vivacqua A, Fasanella G, et al. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17β-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004;279(26):27008–27016.
   PubMed Web of Science ®Google Scholar
• Kajta M, Rzemieniec J, Litwa E, et al. The key involvement of estrogen receptor β and G-protein-coupled receptor 30 in the neuroprotective action of daidzein. Neuroscience 2013;238:345–360.
   PubMed Web of Science ®Google Scholar
• Wong RL, Walker CL. Molecular pathways: environmental estrogens activate nongenomic signaling to developmentally reprogram the epigenome. Clin Cancer Res. 2013;19(14):3732–3737.
   PubMed Web of Science ®Google Scholar
• Bologa CG, Revankar CM, Young SM, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006;2(4):207–212.
   PubMed Web of Science ®Google Scholar
• Dennis MK, Burai R, Ramesh C, et al. In vivo effects of a GPR30 antagonist. Nat Chem Biol. 2009;5(6):421–427.
   PubMed Web of Science ®Google Scholar
• Dennis MK, Field AS, Burai R, et al. Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol. 2011;127(3-5):358–366.
   PubMed Web of Science ®Google Scholar
• Ge X, Guo R, Qiao Y, et al. The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K/akt pathway in endometrial cancer cells. Int J Gynecol Cancer. 2013;23(1):52–59.
   PubMedGoogle Scholar
• Elit L, Hirte H. Novel strategies for systemic treatment of endometrial cancer. Expert Opin Investig Drugs. 2000;9(12):2831–2853.
   PubMed Web of Science ®Google Scholar
• Dong P, Kaneuchi M, Konno Y, et al. Emerging therapeutic biomarkers in endometrial cancer. Biomed Res Int. 2013;2013:1–11.
   Google Scholar
• Gong B, Yue Y, Wang R, et al. Overexpression of microRNA-194 suppresses the epithelial–mesenchymal transition in targeting stem cell transcription factor Sox3 in endometrial carcinoma stem cells. Tumour Biol. 2017;39(6):1010428317706217.
   Google Scholar
• Huszar M, Pfeifer M, Schirmer U, et al. Up‐regulation of L1CAM is linked to loss of hormone receptors and E‐cadherin in aggressive subtypes of endometrial carcinomas. J Pathol. 2010;220(5):551–561.
   PubMed Web of Science ®Google Scholar
• Kent CN, Guttilla Reed IK. Regulation of epithelial–mesenchymal transition in endometrial cancer: connecting PI3K, estrogen signaling, and microRNAs. Clin Transl Oncol. 2016;18(11):1056–1061.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang X, Chen Z, et al. MicroRNA-424 suppresses estradiol-induced cell proliferation via targeting GPER in endometrial cancer cells. Cell Mol Biol. 2015;61(7):96–101.
   PubMed Web of Science ®Google Scholar
• Gaeo M, Cao YK, Xue XO. Effect of daidzein on proliferation of endometrial carcinoma. J Beijing Univ Traditional Chinese Med. 2010;33:162–165.
   Google Scholar
• Jacob V, Hagai T, Soliman K. Structure-activity relationships of flavonoids. COC. 2011;15(15):2641–2657.
   Google Scholar
• Crozier A, Del Rio D, Clifford MN. Bioavailability of dietary flavonoids and phenolic compounds. Mol Aspects Med. 2010;31(6):446–467.
   PubMed Web of Science ®Google Scholar
• Malloy KM, Wang J, Clark LH, et al. Novasoy and genistein inhibit endometrial cancer cell proliferation through disruption of the AKT/mTOR and MAPK signaling pathways. Am J Transl Res. 2018;10(3):784.
   PubMed Web of Science ®Google Scholar
• Gaete L, Tchernitchin AN, Bustamante R, et al. Genistein selectively inhibits estrogen-induced cell proliferation and other responses to hormone stimulation in the prepubertal rat uterus. J Med Food. 2011;14(12):1597–1603.
   PubMedGoogle Scholar
• Sha GH, Lin SQ. Genistein inhibits proliferation of human endometrial endothelial cell in vitro. Chin Med Jl. 2008;23(1):49–53.
   Google Scholar
• Tuli HS, Tuorkey MJ, Thakral F, et al. Molecular mechanisms of action of genistein in cancer: recent advances. Front Pharmacol. 2019;10:1336.
   PubMed Web of Science ®Google Scholar
• Shay JW. Role of telomeres and telomerase in aging and cancer. Cancer Discov. 2016;6(6):584–593.
   PubMed Web of Science ®Google Scholar
• Roy Choudhury S, Karmakar S, Banik NL, et al. Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification. Invest New Drugs. 2010;28(6):812–824.
   PubMedGoogle Scholar